View ValuationGedeon Richter 将来の成長Future 基準チェック /06Gedeon Richter利益と収益がそれぞれ年間1.1%と4.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16.2% 3.4%なると予測されています。主要情報1.1%収益成長率3.39%EPS成長率Pharmaceuticals 収益成長14.5%収益成長率4.2%将来の株主資本利益率16.22%アナリストカバレッジGood最終更新日14 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025お知らせ • Dec 10Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025.お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.お知らせ • Sep 17Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of EndometriosisGedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission ("EC") will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area. RYEQO(R) was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO(R) . Together, these data represent up to two years of efficacy and safety information with RYEQO(R). Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease . Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being. RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, andnorethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO(R) contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen.お知らせ • Feb 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million on February 7, 2023. Geoffrey Burgess, Andrew Bab, Paul Rubin and Richard Ward of Debevoise & Plimpton LLP acted as legal advisor to Gedeon Richter. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of OC Distributors Ltd from Consilient Health on February 7, 2023.お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023業績と収益の成長予測OTCPK:RGED.F - アナリストの将来予測と過去の財務データ ( )HUF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,110,761316,440254,774343,992512/31/20271,033,243288,800231,058313,474612/31/2026957,296262,584219,368314,62563/31/2026925,140229,477225,210290,344N/A12/31/2025928,962232,335209,999276,403N/A9/30/2025901,323227,294242,785305,855N/A6/30/2025903,361221,007213,794274,257N/A3/31/2025878,137239,168222,901285,348N/A12/31/2024857,545239,244215,651279,369N/A9/30/2024839,601211,635150,344217,409N/A6/30/2024811,415229,129124,175193,076N/A3/31/2024798,937187,87464,812135,657N/A12/31/2023805,158158,85029,031123,670N/A9/30/2023825,94895,56351,264146,907N/A6/30/2023855,211123,42658,001152,541N/A3/31/2023844,351157,72058,585152,053N/A12/31/2022802,755169,076114,417185,996N/A9/30/2022755,061242,521108,858175,266N/A6/30/2022694,772198,297103,601169,384N/A3/31/2022657,758149,79293,437160,260N/A12/31/2021630,595139,626-3,393139,904N/A9/30/2021604,708114,689-22,023118,835N/A6/30/2021584,88799,067-14,570120,049N/A3/31/2021566,244102,570-8,138125,391N/A12/31/2020566,776104,68366,882133,520N/A9/30/2020555,12468,48268,707143,298N/A6/30/2020544,96468,13044,478120,856N/A3/31/2020527,60854,12346,506117,941N/A12/31/2019507,79447,135N/A98,214N/A9/30/2019490,66849,451N/A73,813N/A6/30/2019462,57636,071N/A83,211N/A3/31/2019453,15142,857N/A84,171N/A12/31/2018445,48435,348N/A100,343N/A9/30/2018434,07811,939N/A112,349N/A6/30/2018441,99718,899N/A101,483N/A3/31/2018445,6262,997N/A96,266N/A12/31/2017444,3568,885N/A83,747N/A9/30/2017439,82268,291N/A91,977N/A6/30/2017429,20766,829N/A83,315N/A3/31/2017413,02174,992N/A83,140N/A12/31/2016389,69066,200N/A77,419N/A9/30/2016372,68952,016N/A76,144N/A6/30/2016368,53944,525N/A92,174N/A3/31/2016366,88950,419N/A96,778N/A12/31/2015365,22053,863N/A95,047N/A9/30/2015366,63140,482N/A80,771N/A6/30/2015362,90339,300N/A59,468N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RGED.Fの予測収益成長率 (年間1.1% ) は 貯蓄率 ( 3.5% ) を下回っています。収益対市場: RGED.Fの収益 ( 1.1% ) US市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: RGED.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: RGED.Fの収益 ( 4.2% ) US市場 ( 11.8% ) よりも低い成長が予測されています。高い収益成長: RGED.Fの収益 ( 4.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RGED.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 16.2 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/26 19:19終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gedeon Richter PLC 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Simon MatherBarclaysPatrick Andrew WoodBofA Global ResearchGabor BuktaConCorde Securities Ltd.17 その他のアナリストを表示
お知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.
お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.
お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.
お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.
お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.
お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.
お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025
お知らせ • Dec 10Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025.
お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
お知らせ • Sep 17Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of EndometriosisGedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission ("EC") will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area. RYEQO(R) was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO(R) . Together, these data represent up to two years of efficacy and safety information with RYEQO(R). Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease . Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being. RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, andnorethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO(R) contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen.
お知らせ • Feb 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million on February 7, 2023. Geoffrey Burgess, Andrew Bab, Paul Rubin and Richard Ward of Debevoise & Plimpton LLP acted as legal advisor to Gedeon Richter. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of OC Distributors Ltd from Consilient Health on February 7, 2023.
お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023